BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
BCLI$1.14-7.3%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| · · U.S. $ in thousands | ||||||
| ASSETS · · · · | ||||||
| | | | | | | |
| Current Assets: · · · · | ||||||
| Cash and cash equivalents | | $29 | | $187 | ||
| Other accounts receivable | | 86 | | 63 | ||
| Prepaid expenses and other current assets | | 192 | | 135 | ||
| Total current assets | | $307 | | $385 | ||
| | | | | | | |
| Long-Term Assets: | | | | | ||
| Other long-term assets | | $25 | | $22 | ||
| Restricted Cash | | | 247 | | | 184 |
| Operating lease right of use asset (Note 4) | | | 208 | | | 807 |
| Property and Equipment, Net (Note 5) | | 235 | | 434 | ||
| Total Long-Term Assets | | $715 | | $1,447 | ||
| | | | | | | |
| Total assets | | $1,022 | | $1,832 | ||
| | | | | | | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | | | | | ||
| | | | | | | |
| Current Liabilities: | | | | | ||
| Accounts payables | | $7,067 | | $6,080 | ||
| Accrued expenses | | 396 | | 619 | ||
| Short-term loans (Note 11) | | | 967 | | | 300 |
| Operating lease liability (Note 4) | | | 208 | | | 549 |
| Employees related liability | | 2,369 | | 1,430 | ||
| Total current liabilities | | $11,007 | | $8,978 | ||
| | | | | | | |
| Long-Term Liabilities: | | | | | | |
| Operating lease liability (Note 4) | | | — | | | 171 |
| Warrants liability (Note 7) | | | — | | | 447 |
| Total long-term liabilities | | $— | | $618 | ||
| | | | | | | |
| Total liabilities | | $11,007 | | $9,596 | ||
| | | | | | | |
| Stockholders’ Deficit: | | | | | ||
| Stock capital: (Note 8) | | 16 | | 14 | ||
| Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at December 31, 2025 and 100,000,000 shares at December 31, 2024 respectively; Issued and outstanding: 11,034,775 and 6,141,762 shares at December 31, 2025 and December 31, 2024 respectively | | | | | | |
| Additional paid-in-capital | | 227,058 | | 218,974 | ||
| Treasury stocks | | (116) | | (116) | ||
| Accumulated deficit | | (236,943) | | (226,636) | ||
| Total stockholders’ deficit | | $(9,985) | | $(7,764) | ||
| | | | | | | |
| Total liabilities and stockholders’ deficit | | $1,022 | | $1,832 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.